A novel invention developed by a scientist from New York Institute of Technology (NYIT) could revolutionize biological and clinical research and may lead to treatments for cancer, AIDS, Alzheimer's, diabetes, and genetic and infectious diseases. Since the discovery of DNA, biologists have worked to unlock the secrets of the human cell. Scientist Claude E. Gagna, Ph.D., an associate professor at NYIT's School of Health Professions, Be...Tuesday, 13-Feb-2007 / [ Details... ]
The U.S. Court of Appeals for the Federal Circuit has upheld the dismissal of the patent infringement lawsuit filed by Medtronic against BrainLAB AG in 1998. The appellate court affirmed a previous district court ruling that BrainLAB image-guided surgery and radiotherapy products do not infringe any of the patents in suit. In February 2006, the US District Court in Denver, Colorado, dismissed Medtronic's patent infringement lawsuit, fin...Sunday, 11-Feb-2007 / [ Details... ]
QLT Inc. announced that its wholly-owned subsidiary, QLT USA, Inc. (formerly Atrix Laboratories, Inc.) has reached an agreement to settle the litigation captioned "TAP Pharmaceutical Products Inc., Takeda Chemical Industries, Ltd. and Wako Pure Chemical Industries, Ltd. v. Atrix Laboratories, Inc. and Sanofi-Synthelabo Inc.," # 03-C-7822, United States District Court for the Northern District of Illinois and the appeal pending therefrom in the United St...Sunday, 11-Feb-2007 / [ Details... ]
Human DNA patents are unlikely to be the barrier to medical and scientific innovation that they were first feared to be, according to new findings published this week. In fact in recent years new guidelines at patent offices, legal developments, commercial sentiment and the growing volume of genetic information in the public domain have together raised the bar on patentability of genes and other genetic material.In particular, rigorous examination and prohibitive costs are discouraging sp...Thursday, 8-Feb-2007 / [ Details... ]
Martinsried-based drug discovery and development company 4SC AG announced today that the US Patent and Trademark Office (ASPTO) has granted the patent with the US patent number 7,176,241 for its drug candidate SC12267. This patent protects the DHODH inhibitor that is used by 4SC to treat rheumatoid arthritis and is currently undergoing testing in clinical phase IIa. In addition, the patent also covers further back-up substances related to SC12267, m...Tuesday, 6-Feb-2007 / [ Details... ]
Odyssey Thera announced today that on January 9, 2007, the United States Patent and Trademark Office granted U.S. Patent No. 7,160,691. On January 23, 2007, the USPTO also granted U.S. Patent No. 7,166,424. The invention covered by US 7,160,691 protects Protein-fragment Complementation Assays (PCAs) based on fragments of luminescent proteins. These assays exploit the wide dynamic range and signal-to-background ratios that are the hallmarks ...Monday, 5-Feb-2007 / [ Details... ]
GlaxoSmithKline has issued an update on US patent litigation regarding Valtrex (valacyclovir), an antiviral drug used for the treatment and suppression of genital herpes, herpes zoster (shingles), and cold sores. In May 2003, GSK filed a patent infringement suit in the US District Court of New Jersey against Ranbaxy alleging that its generic product would infringe GSK's basic "composition of matter" patent (4957924) for Valtrex, which expires in Ju...Monday, 5-Feb-2007 / [ Details... ]
The Swiss pharmaceutical giant Novartis is in court in India this week challenging the country's patent laws.The drug company is attempting to overturn the Indian government's rejection of its attempt to patent a new version of leukemia drug Gleevec which is known in Europe and India as Glivec.AIDS activists say if Novartis wins the civil suit, it will have ramifications which could leave millions without access to affordable medicine, ...Tuesday, 30-Jan-2007 / [ Details... ]
Nventa Biopharmaceuticals has announced that the U.S. Patent and Trademark Office has issued Patent Number 7,157,089 to Nventa.The patent provides coverage for compositions of fusion proteins comprised of an influenza antigen fused to a heat shock protein (Hsp), as well as DNA encoding such fusion proteins and their use in immunotherapy. In addition, the Company announced that the corresponding European Patent (EP 941,315 B1) has passe...Tuesday, 30-Jan-2007 / [ Details... ]
Archus Orthopedics, Inc. has announced that the European Patent Office has confirmed the validity of its patent number EP-B-1223872 following an Opposition that concluded with oral proceedings on January 10, 2007 in Munich, Germany. This patent, originally issued to Archus on December 22, 2004, discloses the surgical method of replacing the natural facet joint with a prosthesis carried by the pedicle. Unlike the United States, European...Tuesday, 30-Jan-2007 / [ Details... ]